CN
 
Current location： Home > R&D
Commitments
Adhere to the pursuit of high quality
R&D

At PharmaEase Tech, research and development drive everything we do. With 80% of drug candidates facing solubility challenges, our team focuses on creating innovative solutions to tackle this persistent problem in pharmaceutical research.

Our patented PE-n technology is a scalable, low-cost, and effective solution designed to enhance the solubility and bioavailability of active pharmaceutical ingredients (APIs). By leveraging advanced silica-based platforms, our R & D efforts enable pharmaceutical companies to develop life-saving treatments faster and more efficiently.

We collaborate with leading universities, research institutions, and industry partners to refine our technologies and ensure they meet the highest standards of quality and performance. From early-stage formulation to clinical trials, our R & D initiatives are focused on delivering practical, scalable solutions that meet the demands of modern drug development.

PharmaEase Tech remains committed to pushing the boundaries of pharmaceutical science through continuous R & D. Our goal is simple: to make insoluble drugs soluble and enable better outcomes for patients worldwide.

Our invention is a novel drug formulation method designed to address the pervasive issue of drug solubility.

The key enabler is the special adsorption and desorption properties of nanosurfaces we produced, which can efficiently adsorb the drug molecules under the dry condition and release them inside water.

Our technology is versatile (can be applied to many different drugs), reliable (produces consistent results), affordable, and can be scaled up for mass production.

This blend of qualities suggests that our method could potentially replace multiple current drug formulation technologies and become a general game-changer drug delivery technology for the pharmaceutical industry.

Our goal
Tech remains committed to pushing the boundaries of pharmaceutical science through continuous R & D. Our goal is simple: to make insoluble drugs soluble and enable better outcomes for patients worldwide.
product details
Novel Drug Excipient
The necessity of lipophilicity in drug molecules for effective receptor interaction has led to an increasing number of lipophilic and poorly water-soluble candidates.
Therefore, formulating solutions for solubility enhancement remains a major challenge in the pharmaceutical industry. To address this challenge, we have developed a series of drug excipients (PE-07, PE-12, PE-22) specifically designed to enhance drug solubility.
Bhalani, D.V. Nutan, B., Kumar, A.& Singh Chandel, A.K. Bioavailability EnhancementTechniques for PoorlyAqueous Soluble Drugs and Therapeutics. Biomedicines 10, 2055 (2022)
These excipients have been approval as competitive formulations in both vivo and vitro compared to mature products and demonstrating universal effectiveness with various APIs.

The unique feature of these PharmaEase excipients lies in their mesopore size, which allows them to confine the API at a molecular scale and transform it into an amorphous state. Additionally, the convex surface of these excipients, covered with a high density of Si-OH groups, facilitates the adsorption of APIs under dry conditions and enables their rapid release in aqueous solutions.